. (www.anavex.com) is a clinical-stage company engaged in the development of novel drug candidates to treat Alzheimer’s disease, other CNS diseases and various types of cancer. ANAVEX 2-73, an orally available drug candidate developed to treat Alzheimer’s disease through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from preclinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®). The combined therapeutic, called ANAVEX PLUS, produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually. Anavex is a publicly traded corporation quoted as AVXL.

ANAVEX PLUS is a “cocktail” of ANAVEX 2-73 and donepezil (Aricept®). ANAVEX 2-73 is an orally available small molecule with multiple modes of action that holds potential to be disease modifying in Alzheimer’s disease. In several Alzheimer’s disease models including Tg2576, ANAVEX 2-73 has shown a reversal of memory loss and neuroprotection. Studies with ANAVEX 2-73 have shown a clear synergistic memory effect of up to 80% in combination with donepezil, and up to 7 points cognition improvement in ADAS-Cog at 12 weeks and 5.5 points at 26 weeks in a human calibrated realistic cortical network computer model. Anavex has filed a patent application for the combination of ANAVEX 2-73 and donepezil.

Dr. Christopher U. Missling, the Chief Executive Officer (CEO) of Anavex, has over 20 years of healthcare industry experience within large pharmaceutical companies, the biotech industry and investment banking. He has been an investment banker in the healthcare practice at Deutsche Bank, serving pharmaceutical, biotech, and diagnostic companies, and most recently was head of healthcare investment banking at Brimberg & Co. in New York. At Aventis (now Sanofi), Dr. Missling worked as head of financial planning on all aspects of financial strategy and M&A. He was the Chief Financial Officer of Curis (NASDAQ: CRIS) and ImmunoGen (NASDAQ: IMGN) where during his tenure shareholder value increased significantly. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management.

Website: http://www.anavex.com

Tags

 
 
 
 

Enjoy this site? Please spread the word :)

RSS
EMAIL
SHARE